Publication | Open Access
<i>Fusobacterium nucleatum</i> Infection in Colorectal Cancer: Linking Inflammation, DNA Mismatch Repair and Genetic and Epigenetic Alterations
70
Citations
68
References
2018
Year
It has been recently reported that the population of <i>Fusobacterium</i>, particularly <i>Fusobacterium nucleatum</i> (<i>Fn</i>), is overrepresented in colorectal cancers and adenomas. The promoting effects of <i>Fn</i> infection on adenoma and/or carcinoma formation have been shown in Apc<sup>Min/+</sup>mice. Characteristics of <i>Fn</i>-associated CRC were identified through studies using human CRC cohorts, and include right-sided colon location, CpG island methylation phenotype-high (CIMP-H), high level of microsatellite instability (MSI-H), and poor patient prognosis. A subset of <i>Fn</i>-associated CRC exhibits a low level of microsatellite instability (MSI-L) and elevated microsatellite alterations in selected tetra-nucleotide repeats (EMAST) induced by translocation of MSH3 from the nucleus to the cytoplasm in response to oxidative DNA damage or inflammatory signals. The association between CIMP/MSI-H and <i>Fn</i>-infection can be explained by the role of the mismatch repair (MMR) protein complex formed between MSH2 and MSH6 (MutSα) to repair aberrant bases generated by ROS to form 7,8-dihydro-8-oxo-guanine (8-oxoG). Clustered 8-oxoGs formed at CpG-rich regions including promoters by ROS is refractory to base excision repair (BER). Under these conditions, MutSα initiates repair in cooperation with DNA methyltransferases (DNMTs) and the polycomb repressive complex 4 (PRC4). DNMTs at damaged sites methylate CpG islands to repress transcription of target genes and promote repair reactions. Thus, continuous generation of ROS through chronic <i>Fn</i> infection may initiate 1) CIMP-positive adenoma and carcinoma in an MSH2/MSH6-dependent manner, and/or 2) MSI-L/EMAST CRC in an MSH3-dependent manner. The poor prognosis of <i>Fn</i>-associated CRC can be explained by <i>Fn</i>-induced immune-evasion and/or chemo-resistance.
| Year | Citations | |
|---|---|---|
Page 1
Page 1